COMPASS Pathways plc to ring Nasdaq Stock Exchange opening bell in celebration of its successful $146.6 million IPO
October 26 2020 - 7:00AM
COMPASS Pathways plc to ring Nasdaq Stock
Exchange opening bell in celebration of its successful $146.6
million IPO
London, UK – 26 October 2020 COMPASS Pathways
plc (Nasdaq: CMPS), a mental health care company dedicated to
accelerating patient access to evidence-based innovation in mental
health, announced that it will ring the Nasdaq Stock Exchange
opening bell today, in celebration of its recently completed
initial public offering.George Goldsmith, CEO and Co-founder,
COMPASS Pathways, will be joined by members of the COMPASS team for
the virtual ceremony, which will begin at approximately 9.20am
Eastern Time, and can be viewed live at
https://livestream.com/nasdaq/live and on the Nasdaq
MarketSite Tower at 43rd Street and Broadway, New York, NY. The
bell ringing will take place at 9.30am Eastern Time, signifying the
start of the day’s trading session. George Goldsmith said, “I
am honoured to be ringing the Nasdaq opening bell on behalf of
everyone at COMPASS Pathways. We are on a mission to transform
mental health care and I know that every member of our 60-person
team shares our strong sense of purpose and our determination to
reduce the personal and economic burden of mental health
suffering.“We have a big vision. We see a world of mental
wellbeing, a world in which mental health isn’t simply the absence
of mental illness but the ability to flourish. Our first priority
is to bring our psilocybin therapy to some of the millions of
people who suffer with treatment-resistant depression. We want to
develop new models of care, supported by evidence from clinical
trials and in the real world.”
-Ends-
About COMPASS PathwaysCOMPASS Pathways plc
(Nasdaq: CMPS) is a mental health care company dedicated to
accelerating patient access to evidence-based innovation in mental
health. Our focus is on improving the lives of those who are
suffering with mental health challenges and who are not helped by
current treatments. We are pioneering the development of a new
model of psilocybin therapy, in which our proprietary formulation
of synthetic psilocybin, COMP360, is administered in conjunction
with psychological support. COMP360 has been designated a
Breakthrough Therapy by the US Food and Drug Administration (FDA),
for treatment-resistant depression (TRD), and we are currently
conducting a phase IIb clinical trial of psilocybin therapy for
TRD, in 20 sites across Europe and North America. We are
headquartered in London, UK, with offices in New York, USA. Our
vision is a world of mental wellbeing.
www.compasspathways.comForward-looking
statementsThis press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended. In some cases, forward-looking
statements can be identified by terminology such as “may”, “might”,
“will”, “could”, “would”, “should”, “expect”, “intend”, “plan”,
“objective”, “anticipate”, “believe”, “contemplate”, “estimate”,
“predict”, “potential”, “continue” and “ongoing,” or the negative
of these terms or other comparable terminology, although not all
forward-looking statements contain these words. The forward-looking
statements in this press release are neither promises nor
guarantees, and you should not place undue reliance on these
forward-looking statements because they involve known and unknown
risks, uncertainties, and other factors, many of which are beyond
COMPASS’s control and which could cause actual results, levels of
activity, performance or achievements to differ materially from
those expressed or implied by these forward-looking
statements.These risks, uncertainties, and other factors include,
among others: preclinical and clinical development is lengthy and
uncertain, and therefore our preclinical studies and clinical
trials may be delayed or terminated, or may never advance to or in
the clinic; and those risks and uncertainties described under the
heading “Risk Factors” in COMPASS’s Prospectus filed with the US
Securities and Exchange Commission (SEC) on 21 September 2020 and
in subsequent filings made by COMPASS with the SEC, which are
available on the SEC’s website at www.sec.gov. Except as required
by law, COMPASS disclaims any intention or responsibility for
updating or revising any forward-looking statements contained in
this press release in the event of new information, future
developments or otherwise. These forward-looking statements are
based on COMPASS’s current expectations and speak only as of the
date hereof.
Enquiries:COMPASS
PathwaysTracy Cheung, tracy@compasspathways.com, +44 7966
309024Amy Lawrence, amy@compasspathways.com, +44 7813
777919Westwicke (for investor enquiries)Stephanie
Carrington, stephanie.carrington@westwicke.com, +1 646 277 1282
COMPASS Pathways (NASDAQ:CMPS)
Historical Stock Chart
From Mar 2024 to Apr 2024
COMPASS Pathways (NASDAQ:CMPS)
Historical Stock Chart
From Apr 2023 to Apr 2024